MASTER-2

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

Arms / Cohorts

Experimental, Arm A:Arm A: Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (MRD - Patients)

Accepting patients

Other:Arm M: Daratumumab + Lenalidomide + Bortezomib + Dexamethasone

Accepting patients

Experimental:Arm C: Teclistamab + Daratumumab (MRD + Patients)

Accepting patients

Active Comparator:Arm D: Daratumumab + Lenalidomide (MRD + Patients)

Accepting patients

Active Comparator:Arm B: Daratumumab + Lenalidomide (MRD - Patients)

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.